Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PALB2, RAD51C, and BARD1 are additional tumor suppressor genes which also mediate repair of double stranded DNA breaks through the HRD pathway and are implicated in hereditary breast (PALB2; BARD1) and ovarian (RAD51C) cancer.
|
30772928 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We identify genetic variants of BRCA1-BARD1 in patients with cancer that exhibit poor protection of nascent strands but retain homologous recombination proficiency, thus defining domains of BRCA1-BARD1 that are required for fork protection and associated with cancer development.
|
31270457 |
2019 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BARD1 mutant reported in cancer failed to bind to OLA1 and rescue the BARD1 knockdown-induced centrosome amplification and reduced its centrosomal localization.
|
29858377 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review is an overview of how BARD1 functions in tumorigenesis with opposite effects in various types of cancer.
|
29292755 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It highlights also experimental evidence for dominant negative, tumor promoting, functions of aberrant isoforms of BARD1 that are associated with and drivers of various types of cancer.
|
26738429 |
2016 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CHD9, a cancer driver gene, was the most significantly altered (4.0% of cases) after ALK.Other genes (PTK2, NAV3, NAV1, FZD1 and ATRX), expressed in neuroblastoma and involved in cell invasion and migration were mutated at frequency ranged from 4% to 2%.Focal adhesion and regulation of actin cytoskeleton pathways, were frequently disrupted (14.1% of cases) thus suggesting potential novel therapeutic strategies to prevent disease progression.Notably BARD1, CHEK2 and AXIN2 were enriched in rare, potentially pathogenic, germline variants.In summary, whole exome and deep targeted sequencing identified novel cancer genes of clinically aggressive neuroblastoma.
|
27009842 |
2016 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BARD1 (BRCA1 associated RING domain protein 1), as an important animal tumor suppressor gene associated with many kinds of cancers, has been intensively studied for decades.
|
27502904 |
2016 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we review the splicing landscape of TP53, BARD1 and AR to illuminate roles for alternative splicing in cancer.
|
24441040 |
2015 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our findings suggest that BARD1 mutations may be regarded as cancer risk alleles and warrant further investigation to determine their actual contribution to non-BRCA1/2 breast and ovarian cancer families.
|
21344236 |
2012 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our finding that BARD1 does not contribute to this risk modification may focus research on other genes that do modify BRCA1/2-associated cancer risk.
|
21393566 |
2011 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although BARD1 splice variants account for a considerable amount of BARD1 mRNA in both cancer and normal colon samples, distinct variants show a cancer-specific regulation pattern.
|
21693656 |
2011 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.
|
20077502 |
2010 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, BARD1 isoform expression is required for cancer cell proliferation, which is compatible with the notion that BARD1 isoforms act as cancer maintenance genes.
|
18089818 |
2007 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, none of these was found to affect the HDR activity of BARD1, suggesting that any increased cancer risk conferred by these mutations is not because of defects in this repair mechanism.
|
17848578 |
2007 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies.
|
16825437 |
2006 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To investigate whether alterations in BARD1 are involved in human breast and ovarian cancer, we used single strand conformation polymorphism analysis and sequencing on 35 breast tumours and cancer cell lines and on 21 ovarian tumours.
|
16061562 |
2005 |